• RNA Pol II Loss and Programmed Cell Death

  2026-10-12

  Harper et al. report that RNA polymerase II inhibition can trigger apoptosis through loss of hypophosphorylated RNA Pol IIA, rather than simply through depletion of transcriptional output. The study introduces the Pol II degradation-dependent apoptotic response (PDAR), while leaving the breadth of its relevance across tissues, therapies and disease settings to further validation.

• What the 2025 tRNA Study Actually Shows

  2026-10-12

  Li, Baranwal and Maerkl report a conceptual advance toward self-regenerating cell-free biochemistry: a PURE transcription–translation system that produces all 21 tRNAs needed for decoding formylmethionine and the 20 standard amino acids while sustaining protein expression. The work supports feasibility of in situ tRNA supply, but it does not demonstrate a fully self-regenerating synthetic cell or complete regeneration of the PURE system.

• Lamotrigine and BBB Evidence: A Better Read

  2026-10-10

  Lamotrigine research benefits from separating sodium-channel pharmacology from blood-brain barrier exposure evidence. This article interprets a 2025 surrogate BBB study through the lenses of permeability, efflux, lysosomal trapping, and translational relevance.

• O-GlcNAcylation Rewires Glycolysis in Bone Formation

  2026-10-09

  The 2024 study by You and colleagues identifies O-GlcNAcylation as a metabolic and signaling bridge linking Wnt3a activity to osteoblastogenesis. Its central mechanistic finding is that Wnt3a-dependent O-GlcNAcylation stabilizes PDK1 at Ser174, promoting aerobic glycolysis and supporting bone formation and fracture healing.

• Low-Dose Cadmium, STAT3, and Lymphangiogenesis

  2026-10-09

  A 2024 study links low-dose cadmium exposure to enhanced lymphangiogenesis through a STAT3–VEGFR3 signaling axis in corneal injury and lymphatic endothelial models. Its cross-model evidence expands environmental toxicology beyond vascular injury alone, while the findings remain limited by model specificity, dose interpretation, and the pharmacological nature of pathway inhibition.

• Atorvastatin, Ferroptosis, and HCC Research Evidence

  2026-10-08

  Atorvastatin is an HMG-CoA reductase inhibitor with established relevance to cholesterol biology and emerging preclinical interest in hepatocellular carcinoma. This overview examines a 2025 study linking atorvastatin to ferroptosis, separates computational associations from experimental findings, and outlines the evidence limits that prevent direct clinical conclusions.

• TMRE Mitochondrial Membrane Potential Assay

  2026-10-08

  The TMRE mitochondrial membrane potential assay kit converts changes in ΔΨm into a red-fluorescence readout. It is useful for mitochondrial function analysis and mitochondrial depolarization measurement, but the signal does not independently prove ATP failure, apoptosis, or necrosis.

• Axitinib: Evidence, Interpretation, and Limits

  2026-10-07

  A source-grounded overview of Axitinib (AG 013736), covering VEGF receptor biology, evidence quality, viability metrics, preclinical interpretation, and the boundaries of conclusions from in vitro and xenograft research.

• Ribociclib Succinate: CDK Inhibitor Evidence

  2026-10-07

  LEE011 succinate is a research CDK inhibitor used to study CDK4/6-linked cell cycle regulation. Product specifications support chemical characterization, while clinical evidence from degarelix-treated prostate cancer addresses a separate testosterone-bounce question and does not establish ribociclib efficacy.

• Approved Drugs and DNA Repair in CRISPR

  2026-10-06

  Macak, Kanis, and Riesenberg report a large repurposing screen that links clinically approved drugs with distinct DNA double-strand break repair outcomes in human induced pluripotent stem cells. The study identifies candidate modulators of NHEJ, MMEJ, and HDR, highlights ESR2 and AOX1 as relevant biological factors, and frames drug-induced repair bias as a potential tool for genome editing and synthetic lethality research.

• HyperScript RT SuperMix for qPCR: Evidence Context

  2026-10-05

  HyperScript RT SuperMix for qPCR is a premixed reverse-transcription solution for two-step qRT-PCR and cDNA synthesis for qPCR. Its manufacturer describes engineered thermal stability, a mixed-primer design, and compatibility with dye- and probe-based detection, while the cited URSA study provides biological context rather than direct validation of this specific reagent.

• C34 TLR4 Inhibitor: Evidence Across Models

  2026-10-05

  C34 is a selective TLR4 inhibitor for investigating inflammatory signaling across macrophage, enterocyte, intestinal, and microglial models. This evidence-focused analysis explains how C34 can serve as a pharmacological reference point while distinguishing reported findings from hypotheses and translational limitations.

• Electroporation for CRISPR Editing in Mouse Zygotes

  2026-10-04

  Hashimoto and Takemoto showed that electroporation could deliver CRISPR/Cas9-related RNA into mouse zygotes without removing the zona pellucida, addressing a throughput limitation of microinjection. Their findings support a scalable conceptual route for embryo genome engineering, while leaving important questions about locus-specific efficiency, embryo viability, and transferability to other systems.

• Nadolol (SQ-11725): Evidence and Research Context

  2026-10-03

  A source-grounded overview of Nadolol (SQ-11725) for cardiovascular and transporter-focused research, distinguishing supplier-described properties from findings in a 2025 mouse pharmacokinetic study that examined Corydalis saxicola alkaloids rather than Nadolol.

• Atorvastatin: Practical Research Workflows

  2026-10-02

  Build reproducible Atorvastatin assays across cholesterol metabolism, vascular cell biology, and ferroptosis-oriented liver cancer research. This guide combines formulation, dose-finding, phenotype validation, and troubleshooting while separating established product data from exploratory protocol recommendations.

8577 records 1/572 page Next 12345 下5页 Last page